MedTrace Logo

Phase 1 Study of Relative Bioavailability of PPI-668 New Tablet Versus Capsule Formulations

NCT02258321 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2015-01-22

No results posted yet for this study

Summary

This study will compare the blood levels of PPI-668 resulting from two different formulations - the current capsule and a new tablet, T003.

Conditions

  • Pharmacokinetic Assessments in Healthy Volunteers

Interventions

DRUG

PPI-668 tablet

DRUG

PPI-668 capsule

Sponsors & Collaborators

  • Presidio Pharmaceuticals, Inc.

    lead INDUSTRY

Principal Investigators

  • Nathaniel Brown, MD · Presidio Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-10-31
Primary Completion
2014-10-31
Completion
2014-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02258321 on ClinicalTrials.gov